-
Although this study concluded that daily therapy with esomeprazole was superior to on-demand therapy, these results remain open to question.
-
A new combination hormone product has been approved for the treatment of menopausal symptoms. Drospirenone (DRSP), a progestin with mineralo-corticoid activity, is combined with estradiol (E2). DRSP is the same progestin found in the popular oral contraceptive, Yasmin®. DRSP-E2 is marketed by Berlex as Angeliq®.
-
Dietary Phytoestrogens and Lung Cancer Risk; Effectiveness of Influenza Vaccine in the Elderly; Why Does Tadalafil Cause Back Pain?
-
Beta-Blockers Therapy for the Treatment of Hypertension; Treatments for Acute Migraine; Statin Therapy for ACS Patients; The Correct Dosing for Onychomycosis; FDA Actions
-
-
-
The most recent HIV data show that about 1 million Americans are living with HIV, and the epidemic is becoming more firmly entrenched in the African American community, who now account for 47% of people estimated to be living with HIV.
-
Name-based reporting of HIV infection has been successful in New York City since it was begun in June 2000, but holes still remain in the surveillance system in which thousands of HIV-infected individuals are lost, according to recent research.
-
The FDA issued an approval on May 31 for a generic formulation of foscarnet sodium injection, 24 mg/mL, 250 mL, and 500 mL single-dose containers, manufactured by Pharmaforce Inc. of Columbus, OH.
-
The Diffusion of Effective Behavioral Interventions (DEBI) list of HIV prevention programs that are evidence-based was compiled by the CDC for the purpose of giving states and community organizations detailed models for providing prevention services.
